nanotech investing Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
nanotech investing Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
nanotech investing Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
nanotech investing Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 14
